Trovafloxavin mesylate

Revision as of 15:50, 13 February 2015 by Gloria Picoy (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{GP}} |genericName=Trovafloxacin mesylate |hasBlackBoxWarning=Yes |blackBoxWarningTitle=<b><span style="color:#FF0000;">TITLE</span></b...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Trovafloxavin mesylate
Black Box Warning
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Gloria Picoy [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Black Box Warning

TITLE
See full prescribing information for complete Boxed Warning.
Trovafloxavin HAS BEEN ASSOCIATED WITH SERIOUS LIVER INJURY LEADING TO LIVER TRANSPLANTATION AND/OR DEATH. TROVAN-ASSOCIATED LIVER INJURY HAS BEEN REPORTED WITH BOTH SHORT-TERM AND LONG-TERM DRUG EXPOSURE. TROVAN USE EXCEEDING 2 WEEKS IN DURATION IS ASSOCIATED WITH A SIGNIFICANTLY INCREASED RISK OF SERIOUS LIVER INJURY. LIVER INJURY HAS ALSO BEEN REPORTED FOLLOWING TROVAN RE-EXPOSURE. TROVAN SHOULD BE RESERVED FOR USE IN PATIENTS WITH SERIOUS, LIFE- OR LIMB-THREATENING INFECTIONS WHO RECEIVE THEIR INITIAL THERAPY IN AN IN-PATIENT HEALTH CARE FACILITY (I.E., HOSPITAL OR LONG-TERM NURSING CARE FACILITY). TROVAN SHOULD NOT BE USED WHEN SAFER, ALTERNATIVE ANTIMICROBIAL THERAPY WILL BE EFFECTIVE.

Overview

Trovafloxavin mesylate is {{{aOrAn}}} {{{drugClass}}} that is FDA approved for the {{{indicationType}}} of {{{indication}}}. There is a Black Box Warning for this drug as shown here. Common adverse reactions include {{{adverseReactions}}}.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

There is limited information regarding Trovafloxavin mesylate FDA-Labeled Indications and Dosage (Adult) in the drug label.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Trovafloxavin mesylate in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Trovafloxavin mesylate in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding Trovafloxavin mesylate FDA-Labeled Indications and Dosage (Pediatric) in the drug label.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Trovafloxavin mesylate in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Trovafloxavin mesylate in pediatric patients.

Contraindications

There is limited information regarding Trovafloxavin mesylate Contraindications in the drug label.

Warnings

TITLE
See full prescribing information for complete Boxed Warning.
Trovafloxavin HAS BEEN ASSOCIATED WITH SERIOUS LIVER INJURY LEADING TO LIVER TRANSPLANTATION AND/OR DEATH. TROVAN-ASSOCIATED LIVER INJURY HAS BEEN REPORTED WITH BOTH SHORT-TERM AND LONG-TERM DRUG EXPOSURE. TROVAN USE EXCEEDING 2 WEEKS IN DURATION IS ASSOCIATED WITH A SIGNIFICANTLY INCREASED RISK OF SERIOUS LIVER INJURY. LIVER INJURY HAS ALSO BEEN REPORTED FOLLOWING TROVAN RE-EXPOSURE. TROVAN SHOULD BE RESERVED FOR USE IN PATIENTS WITH SERIOUS, LIFE- OR LIMB-THREATENING INFECTIONS WHO RECEIVE THEIR INITIAL THERAPY IN AN IN-PATIENT HEALTH CARE FACILITY (I.E., HOSPITAL OR LONG-TERM NURSING CARE FACILITY). TROVAN SHOULD NOT BE USED WHEN SAFER, ALTERNATIVE ANTIMICROBIAL THERAPY WILL BE EFFECTIVE.

There is limited information regarding Trovafloxavin mesylate Warnings' in the drug label.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Trovafloxavin mesylate Clinical Trials Experience in the drug label.

Postmarketing Experience

There is limited information regarding Trovafloxavin mesylate Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Trovafloxavin mesylate Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Trovafloxavin mesylate in women who are pregnant.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Trovafloxavin mesylate in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Trovafloxavin mesylate during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Trovafloxavin mesylate in women who are nursing.

Pediatric Use

There is no FDA guidance on the use of Trovafloxavin mesylate in pediatric settings.

Geriatic Use

There is no FDA guidance on the use of Trovafloxavin mesylate in geriatric settings.

Gender

There is no FDA guidance on the use of Trovafloxavin mesylate with respect to specific gender populations.

Race

There is no FDA guidance on the use of Trovafloxavin mesylate with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Trovafloxavin mesylate in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Trovafloxavin mesylate in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Trovafloxavin mesylate in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Trovafloxavin mesylate in patients who are immunocompromised.

Administration and Monitoring

Administration

There is limited information regarding Trovafloxavin mesylate Administration in the drug label.

Monitoring

There is limited information regarding Trovafloxavin mesylate Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Trovafloxavin mesylate and IV administrations.

Overdosage

There is limited information regarding Trovafloxavin mesylate overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

There is limited information regarding Trovafloxavin mesylate Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Trovafloxavin mesylate Mechanism of Action in the drug label.

Structure

There is limited information regarding Trovafloxavin mesylate Structure in the drug label.

Pharmacodynamics

There is limited information regarding Trovafloxavin mesylate Pharmacodynamics in the drug label.

Pharmacokinetics

There is limited information regarding Trovafloxavin mesylate Pharmacokinetics in the drug label.

Nonclinical Toxicology

There is limited information regarding Trovafloxavin mesylate Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Trovafloxavin mesylate Clinical Studies in the drug label.

How Supplied

There is limited information regarding Trovafloxavin mesylate How Supplied in the drug label.

Storage

There is limited information regarding Trovafloxavin mesylate Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Trovafloxavin mesylate |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Trovafloxavin mesylate |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Trovafloxavin mesylate Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Trovafloxavin mesylate interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Trovafloxavin mesylate Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Trovafloxavin mesylate Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.